Yaoyao Sun Huijun Qi
10.3389/fendo.2022.1038757
Front Endocrinol (Lausanne)
2023 Jan 13;13:1038757.
conbercept anti-vegf (vascular endothelial growth factor) high-risk pdr neovascularization panretinal photocoagulation
CC BY
https://pubmed.ncbi.nlm.nih.gov/36714571/
Diabetes Mellitus / drug therapy Diabetic Retinopathy / drug therapy Diabetic Retinopathy / surgery
Diabetes Mellitus / drug therapy Diabetic Retinopathy / drug therapy Diabetic Retinopathy / surgery Angiogenesis Inhibitors / therapeutic use Humans Laser Coagulation Neovascularization, Pathologic / drug therapy Retrospective Studies KH902 fusion protein Angiogenesis Inhibitors
PMC9880417
36714571
A comparison between the therapeutic effects of Conbercept combined with panretinal photocoagulation and panretinal photocoagulation monotherapy for high-risk proliferative diabetic retinopathy
2023